Study wrapper · #516
Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors.
Editor's note
This is a pre-specified analysis of a randomized, double-blind, placebo-controlled trial evaluating tesamorelin specifically in people with HIV on integrase-inhibitor (INSTI) regimens — an important gap, since tesamorelin's phase III trials predated INSTIs. Among 38 participants on INSTIs at baseline, researchers reported that 12 months of tesamorelin 2 mg was associated with significant declines in visceral fat, hepatic fat fraction, and trunk-to-appendicular fat ratio versus placebo, and was well tolerated with similar adverse-event frequency including hyperglycemia. The sample is small, which widens uncertainty, but the randomized double-blind design and consistency with tesamorelin's established visceral-fat effect make this a credible, supportive finding. It notably shows benefit without worsening glycemic control despite INSTIs' association with weight gain.
Plain-language abstract
Modern HIV treatment often uses integrase-inhibitor drugs, which can add weight and disturb fat tissue — but tesamorelin's original approval trials were done before these drugs were common. Here, researchers analyzed a randomized, double-blind, placebo-controlled trial to see how tesamorelin performed in 38 people already taking integrase inhibitors. Over 12 months, those on tesamorelin (2 mg daily, injected under the skin) showed meaningful reductions in deep belly fat, liver fat, and the ratio of trunk to limb fat compared with placebo. Side effects, including higher blood sugar, occurred at similar rates in both groups, and the treatment was generally well tolerated. Because the study was randomized and blinded, its results carry weight, though the small number of participants means the exact size of the benefit is uncertain. Encouragingly, the fat improvements came without worsening blood-sugar control.